恒瑞医药：HRS9531注射液、HRS-5817注射液临床试验获批准

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trial notifications regarding HRS9531 injection and HRS-5817 injection, allowing for clinical trials in adult patients with obesity or overweight using HRS9531 in combination with HRS-5817 [1] Group 1 - The company has received approval for clinical trials of HRS9531 injection [1] - The clinical trials will focus on adult patients who are obese or overweight [1] - The trials will involve the combination treatment of HRS9531 injection and HRS-5817 injection [1]